Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yves Toiron

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Breast Cancer Research and Treatment|July 28, 2011
Gene expression profiling of breast tumor cell lines to predict for therapeutic response to microtubule-stabilizing agentsGais Kadra, Pascal Finetti, Yves Toiron, et al.
Expert Review of Proteomics|November 5, 2016
How may targeted proteomics complement genomic data in breast cancer?Mathilde Guerin, Anthony Gonçalves, Yves Toiron, et al.
Genes, Chromosomes & Cancer|September 28, 2002
Molecular cytogenetics of the acute promyelocytic leukemia-derived cell line NB4 and of four all-trans retinoic acid-resistant subclonesMarie-Joëlle Mozziconacci, Angelika Rosenauer, Audrey Restouin, et al.
Oncotarget|September 24, 2016
Circulating vascular endothelial growth factor (VEGF) as predictive factor of progression-free survival in patients with advanced chordoma receiving sorafenib: an analysis from a phase II trial of the french sarcoma group (GSF/GETO)Loic Lebellec, François Bertucci, Emmanuelle Tresch-Bruneel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 22, 2013
The histone deacetylase inhibitor abexinostat induces cancer stem cells differentiation in breast cancer with low Xist expressionMarion A Salvador, Julien Wicinski, Olivier Cabaud, et al.
The American Journal of Pathology|October 9, 2002
Distinct and complementary information provided by use of tissue and DNA microarrays in the study of breast tumor markersChristophe Ginestier, Emmanuelle Charafe-Jauffret, François Bertucci, et al.
Plos One|August 22, 2014
Poly(ADP-ribose) polymerase 1 (PARP1) overexpression in human breast cancer stem cells and resistance to olaparibMarine Gilabert, Simon Launay, Christophe Ginestier, et al.
Molecular & Cellular Proteomics : MCP|April 23, 2008
Protein profiling of human breast tumor cells identifies novel biomarkers associated with molecular subtypesAnthony Gonçalves, Emmanuelle Charafe-Jauffret, François Bertucci, et al.
BMC Cancer|October 12, 2018
Prognostic and predictive factors for angiosarcoma patients receiving paclitaxel once weekly plus or minus bevacizumab: an ancillary study derived from a randomized clinical trialLoïc Lebellec, François Bertucci, Emmanuelle Tresch-Bruneel, et al.
Oncotarget|October 19, 2018
Development of parallel reaction monitoring (PRM)-based quantitative proteomics applied to HER2-Positive breast cancerMathilde Guerin, Anthony Gonçalves, Yves Toiron, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Breast Cancer Research and Treatment|July 28, 2011
Gene expression profiling of breast tumor cell lines to predict for therapeutic response to microtubule-stabilizing agentsGais Kadra, Pascal Finetti, Yves Toiron, et al.
Expert Review of Proteomics|November 5, 2016
How may targeted proteomics complement genomic data in breast cancer?Mathilde Guerin, Anthony Gonçalves, Yves Toiron, et al.
Genes, Chromosomes & Cancer|September 28, 2002
Molecular cytogenetics of the acute promyelocytic leukemia-derived cell line NB4 and of four all-trans retinoic acid-resistant subclonesMarie-Joëlle Mozziconacci, Angelika Rosenauer, Audrey Restouin, et al.
Oncotarget|September 24, 2016
Circulating vascular endothelial growth factor (VEGF) as predictive factor of progression-free survival in patients with advanced chordoma receiving sorafenib: an analysis from a phase II trial of the french sarcoma group (GSF/GETO)Loic Lebellec, François Bertucci, Emmanuelle Tresch-Bruneel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 22, 2013
The histone deacetylase inhibitor abexinostat induces cancer stem cells differentiation in breast cancer with low Xist expressionMarion A Salvador, Julien Wicinski, Olivier Cabaud, et al.
The American Journal of Pathology|October 9, 2002
Distinct and complementary information provided by use of tissue and DNA microarrays in the study of breast tumor markersChristophe Ginestier, Emmanuelle Charafe-Jauffret, François Bertucci, et al.
Plos One|August 22, 2014
Poly(ADP-ribose) polymerase 1 (PARP1) overexpression in human breast cancer stem cells and resistance to olaparibMarine Gilabert, Simon Launay, Christophe Ginestier, et al.
Molecular & Cellular Proteomics : MCP|April 23, 2008
Protein profiling of human breast tumor cells identifies novel biomarkers associated with molecular subtypesAnthony Gonçalves, Emmanuelle Charafe-Jauffret, François Bertucci, et al.
BMC Cancer|October 12, 2018
Prognostic and predictive factors for angiosarcoma patients receiving paclitaxel once weekly plus or minus bevacizumab: an ancillary study derived from a randomized clinical trialLoïc Lebellec, François Bertucci, Emmanuelle Tresch-Bruneel, et al.
Oncotarget|October 19, 2018
Development of parallel reaction monitoring (PRM)-based quantitative proteomics applied to HER2-Positive breast cancerMathilde Guerin, Anthony Gonçalves, Yves Toiron, et al.
Pageof 2